The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
The glamour and gloom of glycogen synthase kinase-3
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A molecular mechanism for the effect of lithium on development.
Klein, P. S., & Melton, D. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8455 · Cited by 2,301
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
GSK3 takes centre stage more than 20 years after its discovery
FRAME, S., & COHEN, P. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3590001 · Cited by 1,433
The multifaceted roles of glycogen synthase kinase 3β in cellular signaling
Grimes, C. A., & Jope, R. S. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(01)00011-9 · Cited by 1,423
Self-citationRequirement for glycogen synthase kinase-3β in cell survival and NF-κB activation
Hoeflich, K. P., Luo, J., Rubie, E. A., Tsao, M.-S., Jin, O., & Woodgett, J. R. (2000) · Nature · doi:10.1038/35017574 · Cited by 1,393
GSK-3α regulates production of Alzheimer's disease amyloid-β peptides
Phiel, C. J., Wilson, C. A., Lee, V. M.-Y., & Klein, P. S. (2003) · Nature · doi:10.1038/nature01640 · Cited by 1,196
Role of Glycogen Synthase Kinase-3 in the Phosphatidylinositol 3-Kinase/Akt Cell Survival Pathway
Pap, M., & Cooper, G. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.19929 · Cited by 1,040
Coghlan, M. P., Culbert, A. A., Cross, D. A., Corcoran, S. L., Yates, J. W., Pearce, N. J., Rausch, O. L., Murphy, G. J., Carter, P. S., Roxbee Cox, L., et al. (2000) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00025-9 · Cited by 897
Cdc42 regulates GSK-3β and adenomatous polyposis coli to control cell polarity
Etienne-Manneville, S., & Hall, A. (2003) · Nature · doi:10.1038/nature01423 · Cited by 835
Frame, S., Cohen, P., & Biondi, R. M. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00253-2 · Cited by 701
Cited by
Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases
Beurel, E., Grieco, S. F., & Jope, R. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.016 · Cited by 1,768
Self-citationJacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., Huang, Q., Qin, J., & Su, B. (2006) · Cell · doi:10.1016/j.cell.2006.08.033 · Cited by 1,410
G1 cell-cycle control and cancer
Massagué, J. (2004) · Nature · doi:10.1038/nature03094 · Cited by 1,224
Wnt/β-catenin signaling in cancer stemness and malignant behavior
Fodde, R., & Brabletz, T. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.02.007 · Cited by 785
Glycogen synthase kinase-3 (GSK3): Inflammation, diseases, and therapeutics
Jope, R. S., Yuskaitis, C. J., & Beurel, E. (2007) · Neurochemical Research · doi:10.1007/s11064-006-9128-5 · Cited by 774
Self-citationLTP Inhibits LTD in the Hippocampus via Regulation of GSK3β
Peineau, S., Taghibiglou, C., Bradley, C., Wong, T. P., Liu, L., Lu, J., Lo, E., Wu, D., Saule, E., Bouschet, T., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.029 · Cited by 695
Wnt Signaling Requires Sequestration of Glycogen Synthase Kinase 3 inside Multivesicular Endosomes
Taelman, V. F., Dobrowolski, R., Plouhinec, J.-L., Fuentealba, L. C., Vorwald, P. P., Gumper, I., Sabatini, D. D., & De Robertis, E. M. (2010) · Cell · doi:10.1016/j.cell.2010.11.034 · Cited by 676
Mechanisms underlying differential responses to FGF signaling
Dailey, L., Ambrosetti, D., Mansukhani, A., & Basilico, C. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.007 · Cited by 649
Metabolic control of cell death
Green, D. R., Galluzzi, L., & Kroemer, G. (2014) · Science · doi:10.1126/science.1250256 · Cited by 647
Tau phosphorylation in neuronal cell function and dysfunction
Johnson, G. V. W., & Stoothoff, W. H. (2004) · Journal of Cell Science · doi:10.1242/jcs.01558 · Cited by 624
Self-citationA Wnt–Axin2–GSK3β cascade regulates Snail1 activity in breast cancer cells
Yook, J. I., Li, X.-Y., Ota, I., Hu, C., Kim, H. S., Kim, N. H., Cha, S. Y., Ryu, J. K., Choi, Y. J., Kim, J., et al. (2006) · Nature Cell Biology · doi:10.1038/ncb1508 · Cited by 616
The Unfolded Protein Response Is Activated in Pretangle Neurons in Alzheimer's Disease Hippocampus
Hoozemans, J. J. M., van Haastert, E. S., Nijholt, D. A. T., Rozemuller, A. J. M., Eikelenboom, P., & Scheper, W. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080814 · Cited by 600
Wieman, H. L., Wofford, J. A., & Rathmell, J. C. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-07-0593 · Cited by 593
Brognard, J., Sierecki, E., Gao, T., & Newton, A. C. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.02.017 · Cited by 591
Pharmacological inhibitors of glycogen synthase kinase 3
MEIJER, L., FLAJOLET, M., & GREENGARD, P. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.07.006 · Cited by 584
Bernardi, P., Rasola, A., Forte, M., & Lippe, G. (2015) · Physiological Reviews · doi:10.1152/physrev.00001.2015 · Cited by 577
Beurel, E., & Jope, R. S. (2006) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.07.006 · Cited by 541
Self-citationA Phase II Trial of Tideglusib in Alzheimer's Disease
Lovestone, S., for the ARGO investigators, Boada, M., Dubois, B., Hüll, M., Rinne, J. O., Huppertz, H.-J., Calero, M., Andrés, M. V., Gómez-Carrillo, B., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141959 · Cited by 536
“neurodegenerative diseases [1,2].”
Chong, Z. Z., Li, F., & Maiese, K. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.02.004 · Cited by 536
GSK-3: Functional Insights from Cell Biology and Animal Models
Kaidanovich-Beilin, O., & Woodgett, J. R. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00040 · Cited by 485
The histamine H3 receptor: from gene cloning to H3 receptor drugs
Leurs, R., Bakker, R. A., Timmerman, H., & de Esch, I. J. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1631 · Cited by 485
Glycogen synthase kinase 3: more than a namesake
Rayasam, G. V., Tulasi, V. K., Sodhi, R., Davis, J. A., & Ray, A. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00085.x · Cited by 483
Dong, X. C., Copps, K. D., Guo, S., Li, Y., Kollipara, R., DePinho, R. A., & White, M. F. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.06.006 · Cited by 463
“Targets of Akt include inhibitors of macromolecular synthesis such as GSK3-b (glycogen synthesis) and Tsc2 (protein synthesis); it also phosphorylates mediators of fasting gene expression such as Foxo1 and Crtc2 by SIK2, resulting in their degradation or exclusion from nuclei (Barthel et al., 2005; Dann et al., 2007;…”
Doble, B. W., Patel, S., Wood, G. A., Kockeritz, L. K., & Woodgett, J. R. (2007) · Developmental Cell · doi:10.1016/j.devcel.2007.04.001 · Cited by 448
Tau phosphorylation: physiological and pathological consequences
Stoothoff, W. H., & Johnson, G. V. W. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.06.017 · Cited by 442
Self-citationTherapeutic potential of mood stabilizers lithium and valproic acid:Beyond bipolar disorder
Chiu, C.-T., Wang, Z., Hunsberger, J. G., & Chuang, D.-M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005512 · Cited by 404
Pastorino, J. G., Hoek, J. B., & Shulga, N. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1925 · Cited by 398
The role of mitochondria in protection of the heart by preconditioning
Halestrap, A. P., Clarke, S. J., & Khaliulin, I. (2007) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2007.05.008 · Cited by 390
Regulation of hexokinase binding to VDAC
Pastorino, J. G., & Hoek, J. B. (2008) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-008-9148-8 · Cited by 385
Glycogen Synthase Kinase-3 (GSK3) in Psychiatric Diseases and Therapeutic Interventions
Jope, R., & Roh, M.-S. (2006) · Current Drug Targets · doi:10.2174/1389450110607011421 · Cited by 382
Self-citationInnate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3)
Beurel, E., Michalek, S. M., & Jope, R. S. (2010) · Trends in Immunology · doi:10.1016/j.it.2009.09.007 · Cited by 378
Self-citationGlycogen Synthase Kinase-3: a Putative Molecular Target for Lithium Mimetic Drugs
Gould, T. D., & Manji, H. K. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300731 · Cited by 375
What Are the bona fide GSK3 Substrates?
Sutherland, C. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/505607 · Cited by 345
Glycogen synthase kinase‐3 inhibition is integral to long‐term potentiation
Hooper, C., Markevich, V., Plattner, F., Killick, R., Schofield, E., Engel, T., Hernandez, F., Anderton, B., Rosenblum, K., Bliss, T., et al. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05245.x · Cited by 344
Damage to dopaminergic neurons by oxidative stress in Parkinson's disease (Review)
Guo, J., Zhao, X., Li, Y., Li, G., & Liu, X. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3406 · Cited by 335
Schenck, A., Goto-Silva, L., Collinet, C., Rhinn, M., Giner, A., Habermann, B., Brand, M., & Zerial, M. (2008) · Cell · doi:10.1016/j.cell.2008.02.044 · Cited by 333
Moloney, C. M., Lowe, V. J., & Murray, M. E. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12321 · Cited by 330
GSK3: a possible link between beta amyloid peptide and tau protein
Hernández, F., Gómez de Barreda, E., Fuster-Matanzo, A., Lucas, J. J., & Avila, J. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.011 · Cited by 327
Insulin in Central Nervous System: More than Just a Peripheral Hormone
Duarte, A. I., Moreira, P. I., & Oliveira, C. R. (2012) · Journal of Aging Research · doi:10.1155/2012/384017 · Cited by 322
A phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy
Tolosa, E., Litvan, I., Höglinger, G. U., Burn, D., Lees, A., Andrés, M. V., Gómez‐Carrillo, B., León, T., del Ser, T., & for the TAUROS Investigators (2014) · Movement Disorders · doi:10.1002/mds.25824 · Cited by 320
Macrodomain-containing proteins are new mono-ADP-ribosylhydrolases
Rosenthal, F., Feijs, K. L. H., Frugier, E., Bonalli, M., Forst, A. H., Imhof, R., Winkler, H. C., Fischer, D., Caflisch, A., Hassa, P. O., et al. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2521 · Cited by 315
S6K1 Regulates GSK3 under Conditions of mTOR-Dependent Feedback Inhibition of Akt
Zhang, H. H., Lipovsky, A. I., Dibble, C. C., Sahin, M., & Manning, B. D. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.09.019 · Cited by 308
In Vivo Regulation of Glycogen Synthase Kinase-3β (GSK3β) by Serotonergic Activity in Mouse Brain
Li, X., Zhu, W., Roh, M.-S., Friedman, A. B., Rosborough, K., & Jope, R. S. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300439 · Cited by 300
“The phosphorylation state of GSK3 is the most well-characterized mechanism that regulates its activity, although regulation of its subcellular distribution and interactions with GSK3-binding proteins also contribute to controlling its actions (Jope and Johnson, 2004).”
BackgroundInfluentialSelf-citationIs Glycogen Synthase Kinase-3 a Central Modulator in Mood Regulation?
Li, X., & Jope, R. S. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.105 · Cited by 294
Self-citationBeurel, E., Song, L., & Jope, R. S. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.47 · Cited by 288
Self-citationRegulation of BMAL1 Protein Stability and Circadian Function by GSK3β-Mediated Phosphorylation
Sahar, S., Zocchi, L., Kinoshita, C., Borrelli, E., & Sassone-Corsi, P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008561 · Cited by 291
Jolivalt, C. G., Lee, C. A., Beiswenger, K. K., Smith, J. L., Orlov, M., Torrance, M. A., & Masliah, E. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21787 · Cited by 287
APPL1: role in adiponectin signaling and beyond
Deepa, S. S., & Dong, L. Q. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90731.2008 · Cited by 287
A Chaperone-Dependent GSK3β Transitional Intermediate Mediates Activation-Loop Autophosphorylation
Lochhead, P. A., Kinstrie, R., Sibbet, G., Rawjee, T., Morrice, N., & Cleghon, V. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.10.009 · Cited by 283
The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases
Wang, H., Liu, Y., Wang, D., Xu, Y., Dong, R., Yang, Y., Lv, Q., Chen, X., & Zhang, Z. (2019) · Cells · doi:10.3390/cells8121597 · Cited by 279
Shakoori, A., Ougolkov, A., Yu, Z. W., Zhang, B., Modarressi, M. H., Billadeau, D. D., Mai, M., Takahashi, Y., & Minamoto, T. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.07.041 · Cited by 272
HDAC6 Regulates Mitochondrial Transport in Hippocampal Neurons
Chen, S., Owens, G. C., Makarenkova, H., & Edelman, D. B. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010848 · Cited by 270
GSK-3β in DNA repair, apoptosis, and resistance of chemotherapy, radiotherapy of cancer
Lin, J., Song, T., Li, C., & Mao, W. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118659 · Cited by 268
The Mitochondrial Chaperone TRAP1 Promotes Neoplastic Growth by Inhibiting Succinate Dehydrogenase
Sciacovelli, M., Guzzo, G., Morello, V., Frezza, C., Zheng, L., Nannini, N., Calabrese, F., Laudiero, G., Esposito, F., Landriscina, M., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.019 · Cited by 264
Misra, U. K., Deedwania, R., & Pizzo, S. V. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511694200 · Cited by 262
Engel, T., Hernández, F., Avila, J., & Lucas, J. J. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0604-06.2006 · Cited by 260
Skov, S., Pedersen, M. T., Andresen, L., Thor Straten, P., Woetmann, A., & Ødum, N. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0599 · Cited by 259
Kotliarova, S., Pastorino, S., Kovell, L. C., Kotliarov, Y., Song, H., Zhang, W., Bailey, R., Maric, D., Zenklusen, J. C., Lee, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0850 · Cited by 254
Phosphorylation of Serine 468 by GSK-3β Negatively Regulates Basal p65 NF-κB Activity
Buss, H., Dörrie, A., Schmitz, M. L., Frank, R., Livingstone, M., Resch, K., & Kracht, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c400442200 · Cited by 252
Mathews, D. C., Henter, I. D., & Zarate, C. A. (2012) · Drugs · doi:10.2165/11633130-000000000-00000 · Cited by 220
GSK3B polymorphisms alter transcription and splicing in Parkinson's disease
Kwok, J. B. J., Hallupp, M., Loy, C. T., Chan, D. K. Y., Woo, J., Mellick, G. D., Buchanan, D. D., Silburn, P. A., Halliday, G. M., & Schofield, P. R. (2005) · Annals of Neurology · doi:10.1002/ana.20691 · Cited by 205
“These substrates may include molecules that mediate the apoptotic pathway such as -catenin, cyclin D1, and heat shock factor 1.(9)”
BackgroundInfluentialBenedetti, F., Serretti, A., Colombo, C., Lorenzi, C., Tubazio, V., & Smeraldi, E. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.06.050 · Cited by 195
Magnetic field effects in biology from the perspective of the radical pair mechanism
Zadeh-Haghighi, H., & Simon, C. (2022) · Journal of The Royal Society Interface · doi:10.1098/rsif.2022.0325 · Cited by 197
Benedetti, F., Serretti, A., Pontiggia, A., Bernasconi, A., Lorenzi, C., Colombo, C., & Smeraldi, E. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2004.11.022 · Cited by 184
Endocytic control of growth factor signalling: multivesicular bodies as signalling organelles
Dobrowolski, R., & De Robertis, E. M. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3244 · Cited by 170
Substrate and Docking Interactions in Serine/Threonine Protein Kinases
Goldsmith, E. J., Akella, R., Min, X., Zhou, T., & Humphreys, J. M. (2007) · Chemical Reviews · doi:10.1021/cr068221w · Cited by 143
Wnts in adult brain: from synaptic plasticity to cognitive deficiencies
Oliva, C. A., Vargas, J. Y., & Inestrosa, N. C. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00224 · Cited by 162
Vlashi, R., Zhang, X., Wu, M., & Chen, G. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.07.011 · Cited by 165
“Glycogen synthase kinase 3 (GSK-3b) also functions as an intermediator in assisting the Wnt-FGF signaling amalgamation.(232) Moreover, osteoblast differentiation during bone development can be stimulated by Fgf 2 via Wnt pathway where Fgf2 deletion reduced the expression of WNT10B, LRP5 and b-catenin genes.”
BackgroundCoudriet, G. M., He, J., Trucco, M., Mars, W. M., & Piganelli, J. D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015384 · Cited by 155
“resulting in pro-inflammatory cytokine production[5,7,23,24,25,26].”
Next-Generation Surrogate Wnts Support Organoid Growth and Deconvolute Frizzled Pleiotropy In Vivo
Miao, Y., Ha, A., de Lau, W., Yuki, K., Santos, A. J. M., You, C., Geurts, M. H., Puschhof, J., Pleguezuelos-Manzano, C., Peng, W. C., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.07.020 · Cited by 151
“On the other hand, CHIR targeted GSK3 regulates diverse cellular pathways other than Wnt signaling pathway (Jope and Johnson, 2004), leading to undesired off-target effects.”
BackgroundLinking Alzheimer's disease to insulin resistance: the FoxO response to oxidative stress
Manolopoulos, K. N., Klotz, L.-O., Korsten, P., Bornstein, S. R., & Barthel, A. (2010) · Molecular Psychiatry · doi:10.1038/mp.2010.17 · Cited by 150
Reddy, P. H. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.06.012 · Cited by 147
“GSK3 is ubiquitously expressed from yeast tomammals and is recognized as a kinase for a large number of proteins involved in multiple cellular pathways [83].”
BackgroundLithium: the pharmacodynamic actions of the amazing ion
Brown, K. M., & Tracy, D. K. (2013) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125312471963 · Cited by 140
“2006] and is primarily regulated through inhibition of its activity via a combination of factors [Kaidanovick-Beilin and Woodgett, 2011], including phosphorylation, intracellular localisation and sequestration by binding proteins [Doble and Woodgett, 2003; Jope and Johnson, 2004; Kockeritz et al. 2006].”
BackgroundMin, W. W., Yuskaitis, C. J., Yan, Q., Sikorski, C., Chen, S., Jope, R. S., & Bauchwitz, R. P. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.09.017 · Cited by 146
Self-citationNeuroglialpharmacology: Myelination as a shared mechanism of action of psychotropic treatments
Bartzokis, G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.015 · Cited by 142
Regulation of Motor Neuron Specification by Phosphorylation of Neurogenin 2
Ma, Y.-C., Song, M.-R., Park, J. P., Henry Ho, H.-Y., Hu, L., Kurtev, M. V., Zieg, J., Ma, Q., Pfaff, S. L., & Greenberg, M. E. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.037 · Cited by 137
Hurtado, D. E., Molina-Porcel, L., Carroll, J. C., MacDonald, C., Aboagye, A. K., Trojanowski, J. Q., & Lee, V. M.-Y. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0889-12.2012 · Cited by 126
Neurogenesis impairment: An early developmental defect in Down syndrome
Stagni, F., Giacomini, A., Emili, M., Guidi, S., & Bartesaghi, R. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.07.026 · Cited by 120
GSK-3 Is Activated by the Tyrosine Kinase Pyk2 during LPA1-mediated Neurite Retraction
Sayas, C. L., Ariaens, A., Ponsioen, B., & Moolenaar, W. H. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-07-0688 · Cited by 115
Eom, T.-Y., & Jope, R. S. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.015 · Cited by 115
Self-citationSimão, F., Matté, A., Pagnussat, A. S., Netto, C. A., & Salbego, C. G. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2012.08229.x · Cited by 111
Cleavage of Tau by calpain in Alzheimer's disease: the quest for the toxic 17 kD fragment
Garg, S., Timm, T., Mandelkow, E.-M., Mandelkow, E., & Wang, Y. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.09.008 · Cited by 103
Sotiropoulos, I., Catania, C., Riedemann, T., Fry, J. P., Breen, K. C., Michaelidis, T. M., & Almeida, O. F. X. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05613.x · Cited by 97
Timm, T., Balusamy, K., Li, X., Biernat, J., Mandelkow, E., & Mandelkow, E.-M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m706596200 · Cited by 95
Rational therapeutic approaches to progressive supranuclear palsy
Stamelou, M., de Silva, R., Arias-Carrion, O., Boura, E., Hollerhage, M., Oertel, W. H., Muller, U., & Hoglinger, G. U. (2010) · Brain · doi:10.1093/brain/awq115 · Cited by 91
The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics
Pritchard, S. M., Dolan, P. J., Vitkus, A., & Johnson, G. V. W. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01273.x · Cited by 89
“Glycogen synthase kinase 3 (GSK3 ) is often considered to be a ‘tau kinase’ as it efficiently phosphorylates T231 and other AD relevant tau epitopes in vitro and in cells and is likely deregulated in AD brain [38, 39].”
BackgroundSelf-citationTGFβ-induced degradation of TRAF3 in mesenchymal progenitor cells causes age-related osteoporosis
Li, J., Ayoub, A., Xiu, Y., Yin, X., Sanders, J. O., Mesfin, A., Xing, L., Yao, Z., & Boyce, B. F. (2019) · Nature Communications · doi:10.1038/s41467-019-10677-0 · Cited by 86
Glycogen synthase kinase-3 is an early determinant in the differentiation of pathogenic Th17 cells
Beurel, E., Yeh, W.-I., Michalek, S. M., Harrington, L. E., & Jope, R. S. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003511 · Cited by 86
Self-citationRegulation by glycogen synthase kinase-3 of inflammation and T cells in CNS diseases
Beurel, E. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00018 · Cited by 82
Yuskaitis, C. J., Beurel, E., & Jope, R. S. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.06.015 · Cited by 79
Self-citationLambertucci, A. C., Lambertucci, R. H., Hirabara, S. M., Curi, R., Moriscot, A. S., Alba-Loureiro, T. C., Guimarães-Ferreira, L., Levada-Pires, A. C., Vasconcelos, D. A. A., Sellitti, D. F., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050390 · Cited by 67
“GSK3 is considered a key factor in the development of insulin resistance and type II diabetes [36], and GSK3 inhibition improves skeletal muscle insulin resistance in type II diabetic animals [37].”
BackgroundTsai, S.-J., Liou, Y.-J., Hong, C.-J., Yu, Y. W.-Y., & Chen, T.-J. (2008) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500486 · Cited by 66
Role of Akt2 in contraction-stimulated cell signaling and glucose uptake in skeletal muscle
Sakamoto, K., Arnolds, D. E., Fujii, N., Kramer, H. F., Hirshman, M. F., & Goodyear, L. J. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00204.2006 · Cited by 63
“of cellular processes beyond the control of glycogen metabolism (20), and GSK-3 -specific signaling has been reported (31), suggesting that further research concerning the role of contraction-stimulated GSK-3 inhibition will be fruitful in elucidating the molecular mechanisms underlying the complex effects of contract…”
BackgroundJackson, J. B., & Pallas, D. C. (2012) · Neoplasia · doi:10.1593/neo.12768 · Cited by 60
GSK-3β Directly Phosphorylates and Activates MARK2/PAR-1
Kosuga, S., Tashiro, E., Kajioka, T., Ueki, M., Shimizu, Y., & Imoto, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507941200 · Cited by 57
Wilson, E. N., Do Carmo, S., Iulita, M. F., Hall, H., Ducatenzeiler, A., Marks, A. R., Allard, S., Jia, D. T., Windheim, J., & Cuello, A. C. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.169 · Cited by 56
Chu, T., Zhou, H., Lu, L., Kong, X., Wang, T., Pan, B., & Feng, S. (2015) · Regenerative Medicine · doi:10.2217/rme.14.86 · Cited by 49
Deyts, C., Vetrivel, K. S., Das, S., Shepherd, Y. M., Dupré, D. J., Thinakaran, G., & Parent, A. T. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5433-11.2012 · Cited by 47
Soeda, Y., Tsuneki, H., Muranaka, H., Mori, N., Hosoh, S., Ichihara, Y., Kagawa, S., Wang, X., Toyooka, N., Takamura, Y., et al. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0163 · Cited by 38
Elsonbaty, S. M., & Ismail, A. F. M. (2020) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2020.108382 · Cited by 32
Metadata
- Authors
- Jope, R. S., & Johnson, G. V. W.
- Venue
- Trends in Biochemical Sciences
- Publisher
- Elsevier BV
- Published
- 2004-02
- Volume
- 29
- Issue
- 2
- Pages
- 95-102
- ISSN
- 0968-0004 (ISSN-L)
- OpenAlex
- W2064913654
- Cited by
- 1,517
- References
- 71
- FWCI
- 5.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.